Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
The mammalian cell banking sector has witnessed significant growth recently, driven by advancements in biopharmaceuticals and regenerative medicine. As demand for innovative therapies rises, this market is set to expand further, supported by technological progress and increasing research investments. Below, we explore the current market size, growth drivers, key players, trends, and regional outlook shaping this vital industry.
Mammalian Cell Banking Market Size and Growth Trajectory Through 2030
The mammalian cell banking market has experienced rapid expansion in recent years. It is projected to increase from $3.14 billion in 2025 to $3.5 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.3%. This growth during the past period has been primarily fueled by advancements in monoclonal antibody production, the rise in vaccine manufacturing, stricter regulatory quality standards, the expansion of academic research, and the commercialization of biologics.
Looking ahead, the market is forecast to grow even more significantly, reaching $5.31 billion by 2030 with a CAGR of 11.0%. Factors expected to drive this future expansion include progress in gene therapy, the increasing adoption of personalized medicine, developments in biosimilars, growth in cell-based therapy pipelines, and the need for long-term cell traceability. Emerging trends predicted in the coming years involve the standardization of cell line preservation, growth in biopharmaceutical pipelines, expansion of CGMP-compliant cell banks, heightened focus on genetic stability, and greater outsourcing to specialized facilities.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28262&type=smp
What Is Fueling the Mammalian Cell Banking Market’s Expansion?
One of the primary forces propelling the mammalian cell banking market is the growing demand for cell-based therapies. These therapies use living cells that are often modified or engineered to repair, replace, or regenerate damaged tissues and organs, providing targeted treatment options for a variety of diseases. The rising prevalence of chronic and rare diseases has increased the urgency for more effective and specific medical solutions, boosting the need for these therapies.
Mammalian cell banking plays a critical role by offering a reliable and standardized supply of high-quality cells. This ensures consistency, safety, and scalability in developing and manufacturing regenerative treatments. For example, in April 2024, the American Society of Gene and Cell Therapy reported an 11% increase in therapies entering Phase I clinical trials since late 2022, highlighting the growing pipeline of cell-based treatments. This surge clearly supports the expanding mammalian cell banking market.
Segments That Drive Revenue in the Mammalian Cell Banking Market
This report divides the mammalian cell banking market into several key segments:
1) Product Type: Master Cell Bank and Working Cell Bank
2) Cell Type: Including Chinese Hamster Ovary (CHO), Baby Hamster Kidney (BHK), Non-Secreting 0 (NS0), YB2/0 and P2/0, Human Embryonic Kidney 293 (HEK293) and derivatives, and Henrietta Lacks (HELA) cells
3) Storage Type: Liquid Nitrogen, Controlled Rate Freezer, and Flash Freezing
4) Application Areas: Drug Development, Vaccine Production, Gene Therapy, and Monoclonal Antibody Production
5) End Users: Academic and Research Laboratories, Biopharmaceutical Companies, and Contract Research Organizations (CROs)
Further subcategories include master cell bank types such as recombinant cell lines, hybridoma cell lines, primary cell lines, genetically engineered cell lines, and viral vector-producing cell lines. Working cell banks are broken down into CGMP-compliant cell banks, research-grade cell banks, clinical trial cell banks, commercial production cell banks, and stability testing cell banks.
Access The Complete Mammalian Cell Banking Market Report:
https://www.thebusinessresearchcompany.com/report/mammalian-cell-banking-global-market-report
How Innovations Are Influencing Future Growth in the Mammalian Cell Banking Market
Leading companies in this field are focusing on creating novel solutions like stable cell line systems that improve productivity, maintain long-term genetic stability, and optimize biopharmaceutical manufacturing processes. These stable cell lines are genetically modified mammalian cells designed to consistently produce therapeutic proteins with high reproducibility across multiple generations.
For instance, in August 2024, WuXi Biologics introduced the WuXia293 Stable platform, an HEK293-based stable cell line system specifically engineered for producing difficult-to-express biologics. This platform uses proprietary technology to ensure stable expression and quality over extended cell passages, overcoming challenges such as low yields and quality issues common with traditional CHO cell systems. It offers high protein output, improved human-like glycosylation, and scalable production suitable for both clinical and commercial needs.
Key Players Defining the Mammalian Cell Banking Market’s Competitive Landscape
Several major companies dominate the mammalian cell banking market, including Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., Catalent Inc., Sartorius Stedim Biotech S A, Samsung Biologics Co Ltd, CMIC Holdings Co Ltd, WuXi Biologics Inc., Evotec SE, AGC Biologics Inc., GenScript ProBio Co Ltd, Syngene International Limited, KBI Biopharma Inc., Rentschler Biopharma SE, Polpharma Biologics S A, Abzena plc, 53Biologics, Cellistic, GBI Biomanufacturing, ABL Inc, OmniaBio, and uBriGene Biosciences. These firms are actively pursuing growth through innovation, strategic partnerships, and expanding global footprints.
Regional Outlook Reveals North America as the Market Leader
In 2025, North America stood as the largest regional market for mammalian cell banking. The comprehensive market analysis also covers other important regions such as Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing a global perspective on market dynamics and opportunities.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
